Tykerb Efficacy In Breast Cancer Not NICE Enough To Justify Price Tag, Says U.K. Agency
Interim analysis finds GSK's lapatinib and capecitabine combo therapy - at almost $50,000 annually - not cost-effective.
Interim analysis finds GSK's lapatinib and capecitabine combo therapy - at almost $50,000 annually - not cost-effective.